Crab Orchard

Researchers are conducting a Phase 2 study to assess the safety and effectiveness of a drug called MEDI0618 compared to a placebo in adults with episodic migraine. The study includes participants who have not responded to at least two different small molecule migraine preventive treatments and are either eligible but have not used aCGRP therapies or have previously failed one or more aCGRP preventive treatments. This research aims to improve migraine prevention options for these individuals. Participants will receive subcutaneous injections of MEDI0618 or placebo in a double-blind, randomized design. The study has multiple dosing arms including Dose A and three additional doses for the group not previously treated with aCGRP therapies, with participants assigned in a 11 ratio to either active drug or placebo. A separate group who have failed aCGRP therapies will also be randomized 11 to receive MEDI0618 or placebo. The treatment period includes repeated dosing and evaluation of the drugs impact on migraine occurrence. Throughout the study, participants will be monitored for migraine headache days and the severity and disability caused by migraines from baseline through treatment. Evaluations will occur regularly from Day 1 to Day 141, including assessments focusing on migraine frequency between Weeks 9 and 12. Safety and efficacy will be closely observed in a controlled setting, and the study is expected to conclude in May 2027.

Researchers are studying maridebart cafraglutide to evaluate its effect on reducing cardiovascular problems and death in people with atherosclerotic cardiovascular disease who are also overweight or obese. This Phase 3 trial compares maridebart cafraglutide to a placebo, both given alongside standard care, to see if maridebart cafraglutide works better in lowering heart-related risks. Participants will receive either maridebart cafraglutide or a placebo, both administered by subcutaneous injection. The study lasts for up to approximately 35 months, during which researchers monitor several heart and health outcomes. These include heart attacks, strokes, death rates, hospitalizations, blood pressure, body measurements, blood sugar control, cholesterol levels, kidney function, and inflammatory markers. During the trial, participants will have regular assessments including physical exams, blood tests, and monitoring of heart events. Researchers track the time to first major heart-related events and changes in health markers over the study period. Safety is also monitored by recording any adverse events. The total participation time can last nearly three years, allowing careful observation of the effects of the study drug compared to placebo.

Researchers are evaluating the effectiveness and safety of a drug called EVO756 compared to a placebo in adults who have migraine. This study focuses on preventing migraine episodes and is conducted as a phase 2 randomized clinical trial with a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. Participants are assigned to one of three groups one group receives a daily oral dose of EVO756 at Dose 1, another group receives a daily oral dose at Dose 2, and the third group receives a daily placebo. The treatment period lasts for 12 weeks, during which the effects of the drug on migraine prevention are studied. Throughout the study, participants will be monitored for changes in the number of monthly migraine days, headache days, and use of acute migraine medications. Researchers will also track the occurrence of any adverse events up to 16 weeks. The total participation includes regular assessments during the 12-week treatment and follow-up evaluations to measure treatment outcomes and safety.